益髓生血颗粒治疗β-地中海贫血156例临床观察

作者	单位
吴志奎	中国中医科学院广安门医院分子生物学研究室
张新华	中国人民解放军第303医院
李敏	中国中医科学院广安门医院分子生物学研究室
柴立民	中国中医科学院广安门医院分子生物学研究室
刘咏梅	中国中医科学院广安门医院分子生物学研究室
王荣新	中国人民解放军第303医院
蔡辉国	中国医学科学院血液学研究所
黄有文	中国人民解放军第303医院
易杰	辽宁中医学院
王蕾	中国中医科学院广安门医院分子生物学研究室
方素萍	中国中医科学院广安门医院分子生物学研究室
陈智松	中国中医科学院广安门医院分子生物学研究室
朱欲英	中国人民解放军第303医院
陈玉英	中国中医科学院广安门医院分子生物学研究室
吕鑫霞	中国中医科学院广安门医院分子生物学研究室

摘要点击次数: 1699

全文下载次数: 3

中文摘要:

目的研究益髓生血颗粒治疗β-地中海贫血临床效果及安全性。方法在广西高发区用益髓生血颗粒治疗β-地中海贫血,疗程3个月,观察治疗前后临床症状、Hb、RBC、网织红细胞(Ret)、抗碱血红蛋白(HbF)水平变化并进行停药后3～6个月随访及不良反应的观察。结果治疗组患者自疗程第1个月起至3个月结束,Hb、RBC、Ret、HbF等各项血液学参数均有提高,与治疗前比较差异有显著性(P<0.01);中医临床症状改善及动态观察与血液参数提高相一致,与治疗前比较差异有显著性(P<0.01);156例中有效145例,无效11例,总有效率达92.9%。未见明显的不良反应。停药后随访结果显示,疗效维持时间3～4个月。结论益髓生血颗粒治疗β-地中海贫血疗效显著,未见明显的不良反应。为中医药辨证治疗β-地中海贫血提供了一定的依据。

英文摘要:

ObjectiveTo study the clinical effect and security of Yisui Shengxue Granule (YSG) in treating β-thalassemia. MethodsOne hundred and fifty-five patients with β-thalassemia from high-incidence area in Guangxi Zhuang Autonomous Region were treated with YSG for 3 months. Clinical symptoms and levels of hemoglobin (Hb), red blood cell (RBC), reticulocyte (Ret) and hemoglobin F (HbF) were observed before and after treatment, and the adverse reaction occurred in the therapeutic course was observed as well. A 3-6 months follow-up study was performed after withdrawal of YSG. ResultsLevels of Hb, RBC, Ret and HbF obviously elevated, and clinical symptoms markedly improved in patients after treatment since the lst month to the 3rd month (all P<0.01). Dynamical observation showed that the improvement of symptoms was in accordance with the elevation of hemorrheological indexes. The treatment was effective in 145 patients and ineffective in 11, and the total effective rate being 92.9%, without any adverse reaction occurred. Follow-up study showed the therapeutic effect could be sustained for 3 to 4 months. ConclusionYSG has evident effect on β-thalassemia without obvious adverse reaction, which provides a definite basis for treatment of β-thalassemia with TCM.

关闭